Compare ACMR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | BEAM |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2017 | 2020 |
| Metric | ACMR | BEAM |
|---|---|---|
| Price | $50.16 | $31.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $43.00 | ★ $46.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.16 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $880,350,000.00 | $55,701,000.00 |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $16.80 | $26.52 |
| P/E Ratio | $28.92 | ★ N/A |
| Revenue Growth | ★ 20.77 | N/A |
| 52 Week Low | $16.81 | $13.53 |
| 52 Week High | $56.30 | $36.44 |
| Indicator | ACMR | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 56.44 |
| Support Level | $50.80 | $29.80 |
| Resistance Level | $56.30 | $35.34 |
| Average True Range (ATR) | 2.79 | 2.80 |
| MACD | -0.12 | 0.14 |
| Stochastic Oscillator | 49.09 | 55.79 |
ACM Research Inc supplies advanced, innovative capital equipment developed for the world-wide semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.